StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta (SRPT), Summit Therapeutics (SMMT) Enter Licensing Agreement for Utrophin Modulator Pipeline
October 4, 2016 7:02 AM
Sarepta Therapeutics (Nasdaq: SRPT) and Summit Therapeutics plc (Nasdaq: SMMT) announced that they have entered into an exclusive license and ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Management Comments
Trading Halts
Next Articles
Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal
October 4, 2016 1:38 PM
Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'
October 4, 2016 9:13 AM
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
October 4, 2016 9:01 AM
Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal
October 4, 2016 8:56 AM
Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer
October 4, 2016 8:44 AM
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 4, 2016 7:00 AM
